Results 1,301-1,320 of 4,002 for speaker:Rose Conway Walsh

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: I thank our guests for the work they do. I am following two drugs in particular, namely, Translarna and Spinraza. These drugs are what led me to the issue of rare diseases. I am not a permanent member of this committee. What has shocked me is the lack of transparency, which has been mentioned. Where there is no transparency, there is no trust. That is the real issue we need to tackle....

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: My time is limited because other witnesses are waiting outside. How long does it take, on average, for approval in Scotland?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: That is exactly what I am trying to get at. Is it due to a human blockage or lack of resources? What is it?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: It is obscure. Is Dr. Mitchell clear on the cost-benefit analysis that is used in the context of how many negative or positive externalities are taken into account or how the decision is arrived at? Is it long, short or medium term?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: That is the point. Is the EMA worth anything? Is it of any value at all or are its standards lower than the ones we have here? These treatments are often for children. Does a child in another country differ from one here? Why do we not take the EMA's decisions and say "Now we are here, what is the other part we need to get in order to get it approved in our country?" I cannot understand...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: That is right.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: I understand that.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: As Ms McGrath knows, in many of these cases, time is the one thing we do not have. I have significant issues with the cost because it is not negotiated. We are taking a headline cost and working out the cost-benefit analysis on that basis but we cannot hope to do so when the drug company is giving a cost expecting it to be negotiated, and rightly so - it would happen in any business...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: We need to get it right all the time because it was not the case with of Translarna.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: A total of 22 countries have approved that drug.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: With regard to the impact of delays in the BeNeLuxA countries, we know the situation regarding Spinraza in all of the BeNeLuxA countries. Surely we can use that as a lever. The children are being admitted to ICU. Even taking out the inhumane aspect and the distress caused, the additional costs are building up in trying to-----

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: It is a shame that the clinicians are not involved in the decision-making. We are lucky, in a country of this size, that we have well qualified clinicians, yet their opinions are just dismissed. There is protectionism within the system that certainly does not serve either the clinicians or the families and those who need the solutions and treatment.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Rose Conway Walsh: The Minister needs to challenge it.

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: I thank Mr. Brennan for his presentation. What interaction has Bord Bia had with its British partners which play a similar role? Has it looked at how many transactions somebody who is exporting a single product might have to make after Brexit? In the event that there is a hard Brexit, at what tariffs could we be looking in the absence of an agreement on the customs union? Will the...

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: I was referring to engagement in the context of opposing a hard Brexit and them using their influence similarly to organisations in the North. I took what Mr. Brennan said for granted because I know Bord Bia is active in engaging with them on a day-to-day basis.

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: Has Bord Bia conducted stress tests on the companies that are exporting? How far down the supply chain will it go? What impact will it have on beef farmers, for example? Are they looking at a further price cut?

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: How much is that out of?

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: It is all spent.

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: I would just like-----

Joint Oireachtas Committee on Agriculture, Food and the Marine: Implications of Brexit for Agriculture Sector: Discussion (Resumed) (20 Nov 2018)

Rose Conway Walsh: My question on transactions was not answered.